CA2372742A1 - Animaux transgeniques doubles utilises comme modeles dans les maladies neurodegenaratives - Google Patents

Animaux transgeniques doubles utilises comme modeles dans les maladies neurodegenaratives Download PDF

Info

Publication number
CA2372742A1
CA2372742A1 CA002372742A CA2372742A CA2372742A1 CA 2372742 A1 CA2372742 A1 CA 2372742A1 CA 002372742 A CA002372742 A CA 002372742A CA 2372742 A CA2372742 A CA 2372742A CA 2372742 A1 CA2372742 A1 CA 2372742A1
Authority
CA
Canada
Prior art keywords
human
animal
protein
sequence
tau
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002372742A
Other languages
English (en)
Inventor
Hugo Alfons Gabriel Geerts
Koenraad Frederic Florentina Spittaels
Chris Van Den Haute
Freddy Kamiel Van Leuven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9915574.9A external-priority patent/GB9915574D0/en
Application filed by Individual filed Critical Individual
Publication of CA2372742A1 publication Critical patent/CA2372742A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0312—Animal model for Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne un acide nucléique vecteur comprenant : (a) une séquence nucléotidique codant une protéine Tau humaine ; (b) une séquence capable de diriger l'expression de la protéine Tau humaine dans le système nerveux d'un animal non humain ; et (c) une séquence de ciblage qui facilite l'intégration dudit vecteur dans le génome de l'animal afin d'empêcher l'expression de la protéine Tau équivalente ou d'une protéine liée ou équivalente de l'animal en faveur de la protéine Tau humaine. Dans un autre aspect, l'invention concerne un acide nucléique vecteur comprenant : (a) une séquence nucléotidique codant une protéine humaine capable de moduler la protéine Tau humaine ; (b) une séquence capable de diriger l'expression de la protéine précitée dans le système nerveux de l'animal ; et (c) une séquence de ciblage capable de faciliter l'intégration dudit vecteur dans le génome de l'animal facultativement en une position correspondant à une séquence dans l'animal codant un équivalent de la protéine humaine précitée, de façon à empêcher l'expression de la séquence équivalente en faveur de la protéine humaine capable de moduler la protéine Tau humaine. On utilise les vecteurs de l'invention pour fabriquer un animal transgénique non humain en (a) introduisant dans une cellule embryonnaire de l'animal un ou plusieurs acides nucléiques vecteurs décrits ci-dessus ; (b) en introduisant l'embryon de l'étape (a) précitée dans un animal femelle ; (c) en maintenant la femelle dans l'étape (b) jusqu'à ce que l'embryon se soit suffisamment développé et naisse ; et (d) en maintenant en vie l'animal transgénique obtenu.
CA002372742A 1999-07-02 2000-06-30 Animaux transgeniques doubles utilises comme modeles dans les maladies neurodegenaratives Abandoned CA2372742A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9915574.9 1999-07-02
GBGB9915574.9A GB9915574D0 (en) 1999-07-02 1999-07-02 Transgenic animals as models for neurodegenerative disease
GBGB0002674.0A GB0002674D0 (en) 1999-07-02 2000-02-04 Transgenic animals as models for neurodegenerative disease
GB0002674.0 2000-02-04
PCT/EP2000/006171 WO2001002552A2 (fr) 1999-07-02 2000-06-30 Animaux transgeniques utilises comme modeles dans les maladies neurodegeneratives

Publications (1)

Publication Number Publication Date
CA2372742A1 true CA2372742A1 (fr) 2001-01-11

Family

ID=26243577

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002372742A Abandoned CA2372742A1 (fr) 1999-07-02 2000-06-30 Animaux transgeniques doubles utilises comme modeles dans les maladies neurodegenaratives

Country Status (8)

Country Link
EP (1) EP1216297A2 (fr)
JP (1) JP2003504015A (fr)
AU (1) AU782281B2 (fr)
CA (1) CA2372742A1 (fr)
IL (1) IL147406A0 (fr)
NO (1) NO20020010L (fr)
NZ (1) NZ515956A (fr)
WO (1) WO2001002552A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799535B1 (en) 1997-12-09 2010-09-21 Arch Development Corporation Methods for identifying factors that control the folding of amyloid proteins of diverse origin
GB0012056D0 (en) * 2000-05-18 2000-07-12 Consejo Superior Investigacion Model for neurodegenerative disease
US7098374B2 (en) * 2001-02-09 2006-08-29 University Of Florida Research Foundation, Inc. Human disease modeling using somatic gene transfer
ATE382704T1 (de) 2001-02-15 2008-01-15 Univ Chicago Verfahren zum nachweis in hefe für mittels die proteinfaltung beeinflussen
GB0104685D0 (en) * 2001-02-26 2001-04-11 Leuven K U Res & Dev Tau-opathy model
GB0126988D0 (en) * 2001-11-09 2002-01-02 Univ London Disease model
AU2003246664B2 (en) * 2002-07-12 2007-06-14 Axon Neuroscience Se Transgenic animal expressing Alzheimer's tau protein
JP5558049B2 (ja) * 2009-08-21 2014-07-23 泰造 谷口 非ヒトモデル動物を用いたパーキンソン症候群の検査方法
KR101890978B1 (ko) 2014-06-17 2018-08-24 서울대학교산학협력단 알츠하이머 질환 모델용 형질전환 돼지 및 이의 용도

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9316727D0 (en) * 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease

Also Published As

Publication number Publication date
NO20020010D0 (no) 2002-01-02
NO20020010L (no) 2002-01-02
NZ515956A (en) 2004-04-30
JP2003504015A (ja) 2003-02-04
WO2001002552A3 (fr) 2001-12-20
EP1216297A2 (fr) 2002-06-26
AU782281B2 (en) 2005-07-14
WO2001002552A2 (fr) 2001-01-11
IL147406A0 (en) 2002-08-14
AU6267300A (en) 2001-01-22

Similar Documents

Publication Publication Date Title
Von Koch et al. Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice
US6187992B1 (en) Transgenic mouse having a disrupted amyloid precursor protein gene
JPH07132033A (ja) アルツハイマー病モデルトランスジェニック動物
US7161060B1 (en) Transgenic mice comprising a genomic human tau transgene
AU782281B2 (en) Transgenic animals as models for neurodegenerative disease
JP5070236B2 (ja) 神経変性性障害のトランスジェニック動物モデル
US5777194A (en) Gene-targeted mice with humanized Aβ sequence and Swedish FAD mutation
US20060168673A1 (en) Transgenic animals as models for neurodegenerative disease
ZA200110477B (en) Transgenic animals as models for neurodegenerative disease.
AU2001262482B2 (en) Model for neurodegenerative disease
CA2706535A1 (fr) Expression de proteine bri modifiee de mammiferes transgeniques
US20030093822A1 (en) Transgenic animal model of neurodegenerative disorders
CA2295861C (fr) Methode de preparation d'un animal transgenique non-humain exprimant le p25
AU2001262482A1 (en) Model for neurodegenerative disease
CA2814737C (fr) Utilisation de peptide beta-42 pour reduire une deficience cognitive chez un sujet
US6958433B2 (en) Transgenic mice overexpressing aspartyl protease 2 (ASP2)
Von Koch Molecular analysis of a homologue of the mouse beta-amyloid precursor protein, APLP2: Isolation of APLP2cDNA, characterization of the APLP2 gene promoter and gene targeting of APLP2
Hernández Pérez et al. Model for neurodegenerative diseases
MXPA00001318A (en) Transgenic animals expressing human p25
CA2468453A1 (fr) Methode de preparation d'un animal transgenique non-humain exprimant le p25

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued